These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. Diskus and diskhaler: efficacy and safety of fluticasone propionate via two dry powder inhalers in subjects with mild-to-moderate persistent asthma. Galant SP; van Bavel J; Finn A; Gross G; Pleskow W; Brown A; Hamedani AG; Harding SM Ann Allergy Asthma Immunol; 1999 Mar; 82(3):273-80. PubMed ID: 10094218 [TBL] [Abstract][Full Text] [Related]
63. Appraisal of lens opacity with mometasone furoate/formoterol fumarate combination in patients with COPD or asthma. Maspero J; Cherrez I; Doherty DE; Tashkin DP; Kuna P; Kuo WL; Gates D; Nolte H; Chylack LT Respir Med; 2014 Sep; 108(9):1355-62. PubMed ID: 25044280 [TBL] [Abstract][Full Text] [Related]
64. Efficacy and safety of fluticasone propionate/salmeterol 250/50 mcg Diskus administered once daily. Kerwin EM; Nathan RA; Meltzer EO; Ortega HG; Yancey SW; Schoaf L; Dorinsky PM Respir Med; 2008 Apr; 102(4):495-504. PubMed ID: 18206361 [TBL] [Abstract][Full Text] [Related]
65. Once-daily evening dosing of mometasone furoate administered via a dry powder inhaler does not adversely affect the hypothalamic-pituitary-adrenal axis. Kosoglou T; Cutler DL; Staudinger H; Herron JM Chest; 2010 Jan; 137(1):115-21. PubMed ID: 19749003 [TBL] [Abstract][Full Text] [Related]
66. Pharmacokinetics of mometasone furoate delivered via two dry powder inhalers. Vaidya S; Ziegler D; Tanase AM; Malmqvist U; Kanniess F; Hederer B; Hosoe M Pulm Pharmacol Ther; 2021 Oct; 70():102019. PubMed ID: 33771722 [TBL] [Abstract][Full Text] [Related]
67. Fluticasone propionate powder and lack of clinically significant effects on hypothalamic-pituitary-adrenal axis and bone mineral density over 2 years in adults with mild asthma. Li JT; Ford LB; Chervinsky P; Weisberg SC; Kellerman DJ; Faulkner KG; Herje NE; Hamedani A; Harding SM; Shah T J Allergy Clin Immunol; 1999 Jun; 103(6):1062-8. PubMed ID: 10359887 [TBL] [Abstract][Full Text] [Related]
68. Effect of therapeutic doses of mometasone furoate on cortisol levels in children with mild asthma. Skoner DP; Gentile DA; Angelini B Allergy Asthma Proc; 2010; 31(1):10-9. PubMed ID: 20167141 [TBL] [Abstract][Full Text] [Related]
69. Mometasone furoate (MF) improves lung function in pediatric asthma: A double-blind, randomized controlled dose-ranging trial of MF metered-dose inhaler. Amar NJ; Shekar T; Varnell TA; Mehta A; Philip G Pediatr Pulmonol; 2017 Mar; 52(3):310-318. PubMed ID: 27740721 [TBL] [Abstract][Full Text] [Related]
70. Pharmacokinetics of fluticasone propionate multidose, inhalation-driven, novel, dry powder inhaler versus a prevailing dry powder inhaler and a metered-dose inhaler. Gillespie M; Song S; Steinfeld J Allergy Asthma Proc; 2015; 36(5):365-71. PubMed ID: 26314817 [TBL] [Abstract][Full Text] [Related]
71. Reduction in oral corticosteroid use with mometasone furoate dry powder inhaler improves health-related quality of life in patients with severe persistent asthma. Schmier J; Leidy NK; Gower R J Asthma; 2003 Jun; 40(4):383-93. PubMed ID: 12870834 [TBL] [Abstract][Full Text] [Related]
72. Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study. Price D; Robertson A; Bullen K; Rand C; Horne R; Staudinger H BMC Pulm Med; 2010 Jan; 10():1. PubMed ID: 20051135 [TBL] [Abstract][Full Text] [Related]
73. Osteocalcin, cortisol levels, and bone mineral density in prepubertal children with asthma treated with long-term fluticasone propionate. Ozkaya E; Nursoy MA; Uzuner S; Erenberk U; Çakır E Horm Res Paediatr; 2012; 77(6):351-7. PubMed ID: 22760032 [TBL] [Abstract][Full Text] [Related]
74. Bone mineral density and associated parameters in pre-pubertal children with asthma treated with long-term fluticasone propionate. Ozkaya E; Çakır E; Uzuner S; Erenberk U; Dundaröz MR Allergol Immunopathol (Madr); 2013; 41(2):102-7. PubMed ID: 22405466 [TBL] [Abstract][Full Text] [Related]
75. Efficacy and safety of two dry-powder inhalers for the administration of mometasone furoate in asthma patients. Pereira CA; Vianna FF; Cukier A; Stelmach R; Oliveira JC; Carvalho EV; Gomes EP; Mayo SV; Chibante AM; Domingues CP J Bras Pneumol; 2010; 36(4):410-6. PubMed ID: 20835586 [TBL] [Abstract][Full Text] [Related]
76. Particle size and small airway effects of mometasone furoate delivered by dry powder inhaler. Berger R; Berger WE Allergy Asthma Proc; 2013; 34(1):52-8. PubMed ID: 23406936 [TBL] [Abstract][Full Text] [Related]
77. Adherence to oral montelukast and inhaled fluticasone in children with persistent asthma. Sherman J; Patel P; Hutson A; Chesrown S; Hendeles L Pharmacotherapy; 2001 Dec; 21(12):1464-7. PubMed ID: 11765298 [TBL] [Abstract][Full Text] [Related]
78. Inhaled mometasone furoate: A review of its use in persistent asthma in adults and adolescents. McCormack PL; Plosker GL Drugs; 2006; 66(8):1151-68. PubMed ID: 16789800 [TBL] [Abstract][Full Text] [Related]
79. One-year treatment with mometasone furoate in chronic obstructive pulmonary disease. Calverley PM; Rennard S; Nelson HS; Karpel JP; Abbate EH; Stryszak P; Staudinger H Respir Res; 2008 Nov; 9(1):73. PubMed ID: 19014549 [TBL] [Abstract][Full Text] [Related]
80. Long-term effects of inhaled corticosteroids on bone mineral density in older women with asthma or COPD: a registry-based cohort study. Chen W; Johnson KM; FitzGerald JM; Sadatsafavi M; Leslie WD Arch Osteoporos; 2018 Oct; 13(1):116. PubMed ID: 30374631 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]